<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106572</url>
  </required_header>
  <id_info>
    <org_study_id>AB03</org_study_id>
    <secondary_id>2013-003446-16</secondary_id>
    <nct_id>NCT02106572</nct_id>
  </id_info>
  <brief_title>Therapeutic Instillation of Mistletoe</brief_title>
  <acronym>TIM</acronym>
  <official_title>Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abnoba Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abnoba Gmbh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with
      Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of
      the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM®
      900, in particular, to compare the toxicity of the two treatments. Another secondary
      objective is the treatment efficacy as measured by calculated prognosis for recurrence and
      progression after 1 year, the tumor grading in case of a recurrence and by measurement of
      Quality of Life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, active-controlled, prospective, multinational Phase III
      confirmative study with 2 treatment groups and an adaptive design (Bauer and Köhne, 1994).
      The study is designed to compare the efficacy of treatment with abnobaVISCUM® 900 with
      Mitomycin C (MMC). Patients with completely resected superficial bladder carcinoma (Stage Ta)
      with an intermediate risk classification according to the European Association of Urology
      (EAU, update 2013) and with one immediately post operative MMC 40 mg intravesical
      instillation will be eligible for inclusion in the study.

      The study comprises a screening period of not more than 6 weeks, a treatment period of 12
      months for abnobaVISCUM® 900 and MMC and a follow-up period of 12 months. Patients will be
      screened within 6 weeks after the transurethral resection of the bladder (TURB) and the
      immediately post operative MMC 40 mg intravesical instillation. A re-resection should be
      performed before inclusion if indicated. Every patient is to provide written informed consent
      before any study related procedures will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blind Review in accordance with with ICH-Biostatistics Guideline ICH E9</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to tumor recurrence</measure>
    <time_frame>up to two years</time_frame>
    <description>The primary objective of the study is to assess the efficacy of abnobaVISCUM® 900. Primary efficacy criterion will be the time to tumor recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and tolerability of the study medication</measure>
    <time_frame>up to two years</time_frame>
    <description>The secondary objective, namely safety including toxicity and tolerability of the study medication, will be assessed by the monitoring of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE), laboratory assessments (hematology, biochemistry and urinalysis) and a global judgment of tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis after 1 year for recurrence and progression</measure>
    <time_frame>1 year</time_frame>
    <description>A secondary efficacy endpoint is prognosis after 1 year for recurrence and progression, estimated by the European Organization for Research and Treatment of Cancer (EORTC) Bladder Cancer Calculator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to two years</time_frame>
    <description>A secondary efficacy endpoint is measurement of Quality of Life with the EORTC QLQ-C30 and BLS24 questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor grading</measure>
    <time_frame>up to two years</time_frame>
    <description>A secondary efficacy endpoint is the tumor grading in case of a recurrence by cytology, ultrasound, and cystoscopy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">546</enrollment>
  <condition>Superficial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>abnobaVISCUM 900</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravesical instillation of abnobaVISCUM 900</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravesical instillation of Mitomycin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abnobaVISCUM 900</intervention_name>
    <description>intravesical instillation of abnobaVISCUM 900 13 times during treatment period</description>
    <arm_group_label>abnobaVISCUM 900</arm_group_label>
    <other_name>viscum album extract</other_name>
    <other_name>mistletoe extract</other_name>
    <other_name>abnobaVISCUM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>intravesical instillation of Mitomycin C 10 times during treatment period</description>
    <arm_group_label>Mitomycin C</arm_group_label>
    <other_name>MMC</other_name>
    <other_name>Mitomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent for data protection and willingness to
             participate and comply with the study protocol prior to any study-related procedures

          -  Completely resected (detrusor muscle in the TUR specimen according to need)
             superficial bladder carcinoma (Stage Ta) with classification as intermediate-risk
             according to the EAU (update 2013) and one immediately post operative intravesical MMC
             instillation of 40 mg, completed re-resection if indicated

          -  Karnofsky Performance Status of 50% to 100% (corresponding to Eastern Cooperative
             Oncology Group (ECOG) Performance Status of 0 to 2)

          -  Life expectancy of ≥ 2 years at the time point of study inclusion

          -  Normal renal and liver function, normal cardiac and hematology profiles (patients with
             laboratory values slightly outside the reference range may be included, unless the
             investigator considers the abnormality as clinically significant)

          -  Female patients of childbearing potential must have a negative pregnancy test (β-human
             chorionic gonadotropin test) at Screening. Pregnancy during the treatment period
             including 12 weeks after the last instillation has to be excluded

        Exclusion Criteria:

          -  Locally infiltrative or metastatic bladder tumor (Stage T2 or greater), low-risk Ta
             tumor (primary, solitary, LG/G1, &lt;3 cm, no CIS) or high-risk tumors according to EAU
             classification, update 2013 (T1; HG/G3; CIS; multiple and recurrent and large [&gt;3 cm]
             Ta G1/G2 tumors [all conditions must be present at this point], presence of upper
             urinary tract tumors or lesions which were not completely removed by TURB

          -  Urinary tract infection, benign prostatic obstruction grade II or III, neurogenic
             bladder, stress incontinence, bladder or urethral diverticula, fistulas or urethral
             stenosis

          -  Patients with acute systemic illness, such as inflammatory infections with fever &gt;
             38°C

          -  Patients with previous recurrence of a superficial bladder cancer or radiotherapy of
             the bladder or other intravesical treatment within the last 6 months, or patients with
             previous mistletoe therapy

          -  Patients with other previous or co-existing malignancies or CIS

          -  Patients having any previous or concurrent therapy with a systemic chemo- /
             immunotherapeutical treatment regimen, in particular vinca alkaloids, bleomycine and
             doxorubicine, or patients who are treated with pyroxidine hydrochloride (vitamin B6)

          -  Untreated coagulation disorders or inadequate anticoagulation therapy

          -  Leukocyte count &lt; 4,000/mm3 or platelet count &lt; 100,000/mm3

          -  Serum creatinine &gt; 1.7 mg/dL

          -  Patients with known hypersensitivity to the excipients of the study medication
             (monosodium phosphate, disodium phosphate, ascorbic acid)

          -  Patients with a known hypersensitivity to mistletoe products and MMC

          -  Patients who were administered within a 4-week period before Visit 1 any other
             experimental drug under investigation

          -  Male patients planning to father a child or sperm donation from the first
             administration of study medication until 3 months after the last administration of the
             study medication

          -  Male patients unwilling to use barrier contraception ie, condoms and spermicide, from
             the day of first administration of the study medication until 12 weeks after
             administration of the study medication. In case the sexual relation is restricted to
             women fulfilling one of the criteria listed under inclusion criteria for female
             patients the barrier contraception is not necessary.

          -  Patients with a history of alcohol and / or drug abuse

          -  Patients who are unable to be regularly observed, not permitting adequate follow-up
             and compliance to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Tschirdewahn, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Physician of the Urological Clinic of the University Hospital Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Eisenbraun, Dr.</last_name>
    <phone>+49 7231 315050</phone>
    <email>eisenbraun@abnoba.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Theodor Bilharz Research Institute</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek El Leithy, Prof. Dr.</last_name>
      <phone>+2 01222117206</phone>
    </contact>
    <investigator>
      <last_name>Tarek El Leithy, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hani Nour, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Wilmersdorf</city>
        <state>Berlin</state>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Schröder, Dr.</last_name>
      <phone>+49 30 88663500</phone>
    </contact>
    <investigator>
      <last_name>Jörg Schneider, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank König, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Breisgau</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Schultze-Seemann, Prof. Dr.</last_name>
      <phone>+49 761 27028920</phone>
    </contact>
    <investigator>
      <last_name>Wolfgang Schultze-Seemann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cordula Jilg, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG, Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <state>Oberpfalz</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thoeodor Klotz, Prof. Dr.</last_name>
      <phone>+49 0961 3033302</phone>
    </contact>
    <investigator>
      <last_name>Theodor Klotz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siegfried Heida, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Berlin</city>
        <zip>10711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Christoph, PD Dr.</last_name>
      <phone>+49 30 8915025</phone>
    </contact>
    <investigator>
      <last_name>Frank Christoph, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Swetlana Kantor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Zillmann, Dipl.-Med.</last_name>
      <phone>+49 30 4853868</phone>
    </contact>
    <investigator>
      <last_name>Roger Zillmann, Dipl.-Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kirschner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Bonn-Rhein-Sieg</name>
      <address>
        <city>Bonn</city>
        <zip>53177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhold Schaefer, Dr.</last_name>
      <phone>+49 228 957370</phone>
    </contact>
    <investigator>
      <last_name>Reinhold Schaefer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Lossin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologicum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Swoboda, Dr.</last_name>
      <phone>+49 203 50030420</phone>
    </contact>
    <investigator>
      <last_name>Andreas Swoboda, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Hellmis, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Eisleben Lutherstadt</city>
        <zip>06295</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Eckert, Dr.</last_name>
      <phone>+49 3475 250059</phone>
    </contact>
    <investigator>
      <last_name>Ralf Eckert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Wicht, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Überörtliche urologische Gemeinschaftspraxis</name>
      <address>
        <city>Erkrath</city>
        <zip>40699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Rulf, Dr.</last_name>
      <phone>+49 2104 43048</phone>
    </contact>
    <investigator>
      <last_name>Wolfgang Rulf, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Langhorst, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic of Urology of the University Hospital of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Tschirdewahn, Dr.</last_name>
      <phone>+49 201 7233210</phone>
    </contact>
    <investigator>
      <last_name>Stephan Tschirdewahn, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Niedworok, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maryam Aalamian-Mattheis, Dr.</last_name>
      <phone>+49 172 6523098</phone>
    </contact>
    <investigator>
      <last_name>Maryam Aalamian-Mattheis, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saeed Pooyeh, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22399</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Suttman, PD Dr.</last_name>
      <phone>+49 40 6921440</phone>
    </contact>
    <investigator>
      <last_name>Henrik Suttmann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rolf Eichenauer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Heinsberg</city>
        <zip>52525</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aloys Lappenküper</last_name>
      <phone>+49 2452 3113</phone>
    </contact>
    <investigator>
      <last_name>Aloys Lappenküper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kretz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Herzberg</city>
        <zip>37412</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Werner, Dr.</last_name>
      <phone>+49 5521 71212</phone>
    </contact>
    <investigator>
      <last_name>Thorsten Werner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Herz, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Oliver Grimm, Prof. Dr.</last_name>
      <phone>+49 3641 935206</phone>
    </contact>
    <investigator>
      <last_name>Marc-Oliver Grimm, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Foller, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rug, Dr.</last_name>
      <phone>+49 721 22080</phone>
    </contact>
    <investigator>
      <last_name>Michael Rug, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Frangenheim, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Kempen</city>
        <zip>47906</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Marin, Dr.</last_name>
      <phone>+49 2152 899290</phone>
    </contact>
    <investigator>
      <last_name>Jan Marin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gundula Linnenbrink, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis Studienzentrum Prüner Gang</name>
      <address>
        <city>Kiel</city>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Lehmann, PD Dr.</last_name>
      <phone>+49 431 26042911</phone>
    </contact>
    <investigator>
      <last_name>Jan Lehmann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Bach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Kirchheim unter Teck</city>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rudolph, Dr.</last_name>
      <phone>+49 7021 3200</phone>
    </contact>
    <investigator>
      <last_name>Robert Rudolph, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Wörner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Facharztpraxis Cologne-Study-Group</name>
      <address>
        <city>Köln</city>
        <zip>50968</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Klier, Dr.</last_name>
      <phone>+49 221 362025</phone>
    </contact>
    <investigator>
      <last_name>Jörg Klier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sassan Nazari, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Langenfeld</city>
        <zip>40764</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eberhard Mumperow, Dr.</last_name>
      <phone>+49 2173 82426</phone>
    </contact>
    <investigator>
      <last_name>Eberhard Mumperow, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Rulf, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Leipzig</city>
        <zip>04229</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wito de Schulz, Dipl.-Med.</last_name>
      <phone>+49 341 90238577</phone>
    </contact>
    <investigator>
      <last_name>Wito de Schulz, Dipl.-Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Detlef Nietzsch, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH Klinik für Urologie und Kinderurologie</name>
      <address>
        <city>Marburg/Lahn</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Hegele, Prof. Dr.</last_name>
      <phone>+49 6421 5862575</phone>
    </contact>
    <investigator>
      <last_name>Axel Hegele, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rainer Häußermann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maren Schwickardi, Dr.</last_name>
      <phone>+49 6421 96440</phone>
    </contact>
    <investigator>
      <last_name>Maren Schwickardi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Ludwig, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Facharztpraxis</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Schulze, Dr.</last_name>
      <phone>+49 341 3542755</phone>
    </contact>
    <investigator>
      <last_name>Matthias Schulze, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvio Szymula, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Michelstadt</city>
        <zip>64720</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Weber, Dr.</last_name>
      <phone>+49 6061 925777</phone>
    </contact>
    <investigator>
      <last_name>Alwin Weber, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingo Drehmer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Mühlacker</city>
        <zip>75417</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Weigl, Dr.</last_name>
      <phone>+49 7041 5622</phone>
    </contact>
    <investigator>
      <last_name>Armin Weigl, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Helder, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Mülheim</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Schneider, Prof. Dr.</last_name>
      <phone>+49 208 94067900</phone>
    </contact>
    <investigator>
      <last_name>Tim Schneider, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elke Stagge, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Privatärztliche urologische Studienpraxis</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Feyerabend, Dr.</last_name>
      <phone>+49 170 3809233</phone>
    </contact>
    <investigator>
      <last_name>Susan Feyerabend, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Feyerabend, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologie PANDAMED</name>
      <address>
        <city>Remscheid</city>
        <zip>42853</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc König, Dr.</last_name>
      <phone>+49 2191 291907</phone>
    </contact>
    <investigator>
      <last_name>Marc König, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Schraa, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis - URONEUM</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Maier, Dr.</last_name>
      <phone>+49 07121 694980</phone>
    </contact>
    <investigator>
      <last_name>Simone Maier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schradin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Wesel</city>
        <zip>46483</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Stammel, Dr.</last_name>
      <phone>+49 281 4755590</phone>
    </contact>
    <investigator>
      <last_name>Andreas Stammel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Garcia Schürmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Praxisgemeinschaft</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Telle, Dipl.-Med.</last_name>
      <phone>+49 05361 3769980</phone>
    </contact>
    <investigator>
      <last_name>Jens Telle, Dipl.-Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Reichelt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis DGU MVZ</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Gleißner, Dr.</last_name>
      <phone>+49 0202 248060</phone>
    </contact>
    <investigator>
      <last_name>Jochen Gleißner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dirk Wienhold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologische Facharztpraxis</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Pulte, Dr.</last_name>
      <phone>+49 2405 452680</phone>
    </contact>
    <investigator>
      <last_name>Thomas Pulte, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Wolter, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>superficial bladder cancer</keyword>
  <keyword>viscum album extract</keyword>
  <keyword>mistletoe extract</keyword>
  <keyword>abnobaVISCUM</keyword>
  <keyword>recurrence rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Viscum album peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

